INCY - INCYTE CORP

QQQ $ 447.95 $ -10.91 (-2.37 %)

DIA $ 397.31 $ -6.10 (-1.51 %)

SPY $ 532.92 $ -10.11 (-1.86 %)

TLT $ 98.17 $ 2.97 (3.12 %)

GLD $ 225.36 $ -0.43 (-0.19 %)

Previous Close

$ 64.47

Open

Bid

$ 64.42 x 107

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 50.27 - $ 70.36

Volume

1,942,001

Average Volume

Market Cap

14.07B

Beta (5Y Monthly)

$ 0.52

PE Ratio (TTM)

$ 144.57

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	07-30-2024	06-30-2024	10-Q
2	04-30-2024	03-31-2024	10-Q
3	02-13-2024	12-31-2023	10-K
4	10-31-2023	09-30-2023	10-Q
5	08-01-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	02-07-2023	12-31-2022	10-K
8	11-01-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	02-08-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-04-2021	03-31-2021	10-Q
15	02-09-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-04-2020	06-30-2020	10-Q
18	05-05-2020	03-31-2020	10-Q
19	02-13-2020	12-31-2019	10-K
20	10-30-2019	09-30-2019	10-Q
21	07-30-2019	06-30-2019	10-Q
22	04-30-2019	03-31-2019	10-Q
23	02-14-2019	12-31-2018	10-K
24	10-30-2018	09-30-2018	10-Q
25	07-31-2018	06-30-2018	10-Q
26	05-01-2018	03-31-2018	10-Q
27	02-15-2018	12-31-2017	10-K
28	10-31-2017	09-30-2017	10-Q
29	08-01-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	02-14-2017	12-31-2016	10-K
32	11-01-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-09-2016	03-31-2016	10-Q
35	02-12-2016	12-31-2015	10-K
36	11-03-2015	09-30-2015	10-Q
37	08-04-2015	06-30-2015	10-Q
38	04-30-2015	03-31-2015	10-Q
39	02-17-2015	12-31-2014	10-K
40	10-30-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Deutsche Bank Maintains Hold on Incyte, Ra...
08/01/2024 17:59:06

Deutsche Bank analyst James Shin maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $55 to $60.

Citigroup Maintains Buy on Incyte, Raises ...
07/31/2024 19:33:54

Citigroup analyst David Lebowitz maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $80 to $88.

after-reporting-five-patient-deaths-data-committee-recommends-macrogenics-halt-prostate-cancer-trial

After Reporting Five Patient Deaths, Data ...
07/31/2024 17:45:20

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 202...

JP Morgan Maintains Neutral on Incyte, Rai...
07/31/2024 16:47:57

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $59 to $61.

RBC Capital Maintains Sector Perform on In...
07/31/2024 14:50:29

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $61...

B of A Securities Maintains Neutral on Inc...
07/31/2024 11:13:38

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $62 to...

MacroGenics Achieves $100M In Milestones R...
07/30/2024 20:19:14

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializ...

incytes-q2-earnings-wider-than-expected-loss-pipeline-review-lifts-jakafi-sales-guidance

Incyte's Q2 Earnings: Wider Than Expected ...
07/30/2024 16:57:28

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 5...

Incyte shares are trading higher after the...
07/30/2024 12:55:24

Incyte Forecasts 2024 Jakafi Net Product R...
07/30/2024 11:11:03

2024 Financial Guidance Incyte is raising the low end of its full year 2024 Jakafi revenue guidance as well as updating its fu...

Incyte Q2 2024 Adj. EPS $(1.82) Misses $(1...
07/30/2024 11:03:09

Analyst Ratings For Incyte
07/26/2024 17:00:41

Oppenheimer Maintains Outperform on Incyte...
07/26/2024 16:58:53

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $84 to $81.

sp-500-hits-record-highs-eyes-6th-straight-gain-as-powell-keeps-bears-at-bay-tesla-targets-10th-consecutive-win-bank-stocks-rally-whats-driving-markets-tuesday

S&P 500 Hits Record Highs, Eyes 6th Straig...
07/09/2024 17:47:10

The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecu...

this-crowdstrike-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday

This CrowdStrike Analyst Is No Longer Bull...
07/02/2024 17:32:46

BMO Capital Downgrades Incyte to Underperf...
07/02/2024 09:15:18

BMO Capital analyst Evan Seigerman downgrades Incyte (NASDAQ:INCY) from Market Perform to Underperform and lowers the price ...

Analyst Expectations For Incyte's Future
06/18/2024 14:01:02

Cantor Fitzgerald Reiterates Neutral on In...
06/18/2024 13:46:22

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.

nasdaq-100-sp-500-close-at-record-highs-as-tech-stocks-reclaim-dominance-thursdays-gainers--losers

Nasdaq 100, S&P 500 Close At Record Highs ...
06/13/2024 20:35:42

The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-...

Incyte Announces Preliminary Results Of It...
06/11/2024 12:14:42

Incyte Corporation (NASDAQ:INCY) ("Incyte" or the "Company") announced today the preliminary results of its mod...

CLASS ACTION DEADLINES - JOIN NOW!

08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)

INCYINCYTE CORP

Nasdaq incyte.com

$ 64.44 $ 0.05 (0.08 %)

Friday, 02-Aug-2024 15:59:56 EDT